Study in The Lancet successfully demonstrated endpoints of identifying both vulnerable patients & plaques at a significantly higher risk for subsequent MACE. View now View Now

Logo

Now FDA indicated to identify plaque and patients at increased risk of MACE.

Achieve unparalleled insights with the Makoto™ Imaging System and its accompanying Dualpro™ IVUS + NIRS catheter, the only FDA-cleared dual-modality catheter and imaging system indicated for the identification of patients and plaques at increased risk of major adverse cardiac events (MACE).

Explore the

LRP STUDY RESULTS

 

See the Makoto™

SYSTEM IN ACTION

 

Discover the

IVUS+NIRS TECHNOLOGY

 

Global Products

In 2015, Nipro Corporation acquired lnfraredx, a U.S. Imaging Company, as part of its long-term strategic plan to build a world class cardiovascular brand.

LEARN MORE ABOUT NIPRO

The OKAY II is not yet available for sale in the United States

LRP: Assessment of Coronary Near-Infrared Spectroscopy Imaging to Detect Vulnerable Plaques and Vulnerable Patients

We are Pioneers

developing solutions aimed at conquering vascular disease

SEE WHAT IT TAKES

© 2019 Infraredx™, Inc. All Rights Reserved Powered by Bloom Creative